Altimmune (ALT) announced the appointment of Greg Weaver as CFO, effective immediately. Mr. Weaver will lead the Company’s finance and accounting functions, including SEC reporting and investor relations. Most recently, he was CFO of Cognito Therapeutics, a clinical-stage company targeting neurodegenerative diseases.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALT:
- Options Volatility and Implied Earnings Moves This Week, November 11 – November 15, 2024
- Altimmune announces successful completion of End-of-Phase 2 meeting
- ALT Upcoming Earnings Report: What to Expect?
- Altimmune call volume above normal and directionally bullish
- Altimmune completes enrollment in Phase 2b IMPACT trial of pemvidutide